Abstract Familial hypercholesterolemia (FH), caused by many different mutations in the low-density lipoprotein (LDL)-receptor gene, invariably leads to severe premature coronary heart disease (CHD) in homozygous individuals. Heterozygous FH patients are less severely affected but are still at increased risk of CHD in most populations. Although FH homozygotes in China are affected similarly to those elsewhere, heterozygotes are not detected in the general population and obligate heterozygotes are often not hypercholesterolemic by Western standards. Mutations in the LDLreceptor genes of 10 homozygous FH patients from the Jiang-su province of China and their heterozygous parents were analyzed. These include one large and two minor deletions and eight point mutations: four are predicted to introduce a premature stop codon, five to result in a single amino acid substitution or deletion, and one to produce a protein with an abnormal cytoplasmic tail. Expression of the mutant LDL-receptor cDNAs in vitro confirmed that these mutations impaired LDL-receptor function and that several would cause a receptor-negative phenotype. Thus, the lack of clinical expression in obligate FH heterozygotes is not due to unusually "mild" mutations in the LDL-receptor gene, and other genetic or environmental factors must therefore be important in determining phenotypic expression. (Arierioseler Thromb. 1994;14:85-94.) 
F amilial hypercholesterolemia (FH) is an inher-
ited disorder of lipoprotein metabolism that is caused by mutations in the gene for the lowdensity lipoprotein (LDL) receptor. In Western societies, individuals heterozygous for the disorder show impaired clearance of LDL from the circulation and a marked increase in the concentration of LDL in the plasma. This results in excessive accumulation of cholesterol in the tissues, leading to the formation of xanthomata in the skin and tendons as well as accelerated atherosclerosis that is frequently associated with severe premature coronary heart disease (CHD). 1 Marked variation exists in the severity of the disorder in FH heterozygotes, but it is not known whether this is dependent on the nature of the genetic defect and its precise effect on LDL-receptor function or whether other genetic and environmental risk factors are more important.
Numerous mutations in the LDL-receptor gene have been detected in DNA from affected individuals, and in some cases the effect of these mutations on LDLreceptor function has been fully characterized (for review, see Reference 2) . A classification system has been devised in which five allele categories have been identified, including null, transport-defective, bindingdefective, internalization-defective, and recycling-defective. In many cases each category is associated with mutations in regions of the gene that code for one particular domain of the protein. 3 Defective LDL-their apparently minimal impact on plasma cholesterol levels and coronary disease in heterozygous individuals.
Methods Subjects
Ten apparently unrelated individuals with a clinical diagnosis of FH that was based on a markedly raised concentration of LDL cholesterol in plasma and the presence of skin and tendon xanthomata were studied, together with their parents and siblings when available. Several index patients showed evidence of CHD and some reported a family history of sudden death, but their parents were apparently healthy. The majority of patients were identified as FH homozygotes after their initial presentation at dermatology clinics.
Lipid and Lipoprotein Analyses
Total plasma cholesterol and triglyceride concentrations were measured enzymatically with commercially available kits (Sigma Chemical Co). High-density lipoprotein (HDL) cholesterol was measured after heparin-manganese precipitation of plasma, 11 and LDL cholesterol values were calculated.
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Genetic Analysis
Genomic DNA was isolated from whole frozen blood 13 and transported to London for further studies. Southern blotting of genomic DNA and nucleotide sequencing of polymerase chain reaction (PCR)-amplified exons or pairs of exons of the LDLreceptor gene were carried out as described previously. 14 -15 For restriction-enzyme analysis of PCR products, the unpurified product was digested with the appropriate enzyme in the buffer recommended by the supplier, and the resulting fragments were analyzed on either agarose minigels or nondenaturing polyacrylamide gels (8x10 cm, 10% [wt/vol] acrylamide) when it was necessary to detect fragments less than 100 bp long. 13 PCR products were analyzed on nondenaturing polyacrylamide gels as described above to detect the presence of heteroduplexes. Analysis of single-strand conformational polymorphisms (SSCPs) in ^P-labeled PCR products was carried out on nondenaturing Hydrolink MDE gels (50 cm long and 0.4 mm thick; Hoefer Scientific, Newcastle, UK) following the manufacturer's protocol. Genomic DNA was analyzed for the presence of the apolipoprotein B (apoBJjjop mutation by hybridization of an amplified fragment of the apoB gene with allele-specific oligonucleotides. 16 
Site-Directed Mutagenesis of LDL-Receptor cDNA and Expression of Mutant cDNA Species in Heterologous Cells
Mutations were introduced into pLDLR4, a full-length cDNA for the human LDL receptor, in a mammalian expression vector driven by the SV40 promoter, which was kindly provided by Dr David Russell, University of Texas Southwestern Medical Center, Dallas, Tex. Two fragments of the cDNA (a 3.2-kb EcoRlSac I fragment comprising the 3' part of the coding region and a 2.1-kb Xba \Sph I fragment comprising the 5' part) were cloned into the phagemid pSELECT (Promega Ltd, Chihvorth Research Centre, Southampton, UK). Mutations were introduced into single-stranded DNA from the appropriate phagemid either by using a commercially available kit and following the supplier's protocol (altered sites in vitro mutagenesis kit, Promega Ltd) or directly into the double-stranded plasmid by selecting for ampicillin resistance with a second oligonucleotide to repair the amp site. 17 Mutant plasmids were identified by restriction-enzyme analysis, detection of heteroduplexes or SSCPs of PCR-amplified fragments of plasmid DNA from colonies, 18 or nucleotide sequencing of miniprep plasmid DNA when necessary. The mutant LDLreceptor cDNA inserts were then cloned into pLDLR4 as described, 15 and the presence of the desired mutation in an otherwise unchanged cDNA was confirmed by nucleotide sequencing of large-scale preparation of each mutant plasmid. Mutant and normal pLDLR4 species were expressed transiently in monkey COS cells in culture, and the resultant LDL-receptor protein was analyzed by immunoblotting with monoclonal antibodies to the bovine LDL-receptor protein as described 15 and by ligand blotting with ^I-labeled LDL. 1 ' For some mutations the mutant LDL-receptor cDNA was cotransfected with pSVZneo 20 into an LDL-receptor-deficient Chinese hamster ovary (CHO) cell line Idl-AT 21 kindly provided by Dr M. Krieger, and stable transfectants were isolated essentially as described by Davis and coworkers. 22 Geneticinresistant colonies of transfected cells were picked from the culture dish, and the resultant cell lines were analyzed for stable incorporation of human LDL-receptor cDNA by PCR amplification of DNA in cell extracts with oligonucleotide primers that were located approximately 500 bp apart in the cDNA but were in different exons of the gene. 23 No PCR product was detected in extracts of untransfected CHO Idl-A7 cells or in cells mock-transfected with salmon sperm DNA. Binding, uptake, and degradation of I-labeled LDL by transfected CHO Idl-A7 cells was carried out with procedures originally described by Goldstein and colleagues 24 - 25 for skin fibroblasts; immunoblotting and ligand blotting for COS cells were carried out as described above.
Results
Clinical Details
Clinical details of the 10 homozygous index patients in this study and their parents and siblings are shown in Table 1 . Total plasma cholesterol in the homozygous FH patients ranged from 8.2 to 20.1 mmol/L with a mean value of 15.02 mmol/L, while that in their heterozygous parents varied from as little as 4.4 to 8.9 mmol/L, with a mean of 6.09 mmol/L. LDL cholesterol concentrations followed a similar pattern. The majority of subjects were normotriglyceridemic. All homozygous FH patients had extensive skin and tendon xanthomata, but only those 15 years or older had overt symptoms of CHD. None of their obligate heterozygous parents had any detectable skin or tendon xanthomata, even though some were in their fifth decade.
Identification of Mutations
Southern blotting of genomic DNA digested with Pvu II with a cDNA probe for the 3' end of the LDLreceptor cDNA revealed a possible major deletion of approximately 8 kb in a single allele in one index patient (No. 5 in family 1; Fig la) . Additional blotting experiments showed that the deletion encompassed exons 11 through 14 of the gene and that the patient had inherited this allele from his mother. Southern blots of DNA from the father of this patient and from the remaining nine homozygous patients were identical to those obtained with unaffected individuals, from which we concluded that the mutations responsible for defective LDL-receptor function in these cases were either single base changes or those that involved only a few nucleotides. Haplotype analysis that was based on five polymorphic sites in the gene 15 originally suggested that 5 of the 10 patients could be homozygous at the LDL-receptor gene locus. However, two haplotypes were very frequent in this group, and as described below, two "homozygous" patients had inherited two different mutant alleles with the same background of polymorphisms. viduals were found to be heterozygous for the mutation that was detected in their homozygous child, and there was evidence of consanguinity.
In patient No. 5 in whom one allele had a deletion of exons 11 through 14 as described above, DNA sequencing revealed apparent homozygosity for a single base substitution in exon 12 (Fig lb) . However, since the father of this patient was heterozygous for the substitution, we concluded that the patient was a compound heterozygote who had one allele with a deletion and one allele with a single base change in exon 12.
In three other patients, DNA sequencing of amplified genomic DNA revealed two different mutations in the LDL-receptor gene, and in the families of two of these it could be shown by DNA sequencing that both parents of each patient were heterozygous for a different mutation. The parents of the third patient were no longer alive, but a sibling with a diagnosis of homozygous FH was also found to be carrying the same two mutations in the LDL-receptor gene. One other patient was found to be heterozygous for a deletion of 3 bp in exon 4 that was inherited from the father. No mutation was identified in the allele inherited from the mother. From these observations we concluded that these four index patients were also compound heterozygotes with two different mutant alleles (Table 2 ).
In the three remaining patients with a diagnosis of FH, no mutations were identified in either the coding region or the proposed promoter region of the LDLreceptor gene, either by nucleotide sequencing or SSCP analysis of PCR products. No patient carried the o mutation that can cause the same clinical syndrome as FH.
Several of the mutations destroy or create a restriction-enzyme site in the gene, and all but one of the remaining alleles that carry microdeletions or point mutations can be readily detected as heteroduplexes or by the presence of extra bands on SSCP gels (for example, see Fig 2) , which will facilitate screening for these mutations in other groups of FH patients.
Characterization of Mutant LDL-Receptor Phenotype
In some cases in which the mutation introduced a premature stop codon, it was possible to predict the precise effect that the change in nucleotide sequence would have on the structure of the mutant protein and on the resulting phenotype associated with the mutant allele. In instances where the mutation would be expected to cause a single amino acid substitution, it was less certain that the change was necessarily the underlying cause of FH in the patient, and these mutations were introduced into a full-length cDNA for the human LDL receptor and expressed in heterologous cells. Initially the mutant cDNAs were analyzed by transient expression in COS cells, the results of which are shown in Fig 3a and 3b and summarized in Table 3 .
In these experiments extracts of COS cells that had been mock-transfected with salmon sperm DNA and preincubated with sterol-containing medium to suppress the endogenous LDL receptor contained no immunodetectable LDL-receptor protein (Fig 3a, lane 1) . However, ligand blotting of the same extracts with . PCR products comprising exon 5 from FH 15, his parents, and a normal subject (N) were labeled with pPjdCTP by incubation of the first-round PCR reaction mix (0.1 fit) in a total volume of 10 ^L of fresh reaction mix containing 1.6 fid [a-^JdCTP (specific activity, 3000 Cl/mmol) for two further cycles of amplification under the same conditions. The labeled PCR product (1 fiL of reaction mix) was diluted 10-fold with denaturing solution (0.1% wt/vol sodium dodecyl sulfate, 10 mmol/L EDTA), and 5 /iL of the diluted solution was mixed with an equal volume of loading buffer (95% vol/vol formamlde, 10 mmol/L NaOH, and dyes). The mix was heated for 5 minutes at 10O°C and snap-cooled on ice, and then 2 /iL was applied to an MDE gel (0.4 mm thick and 50 cm long) prepared according to the recommendations of the supplier (Hoefer Scientific); electrophoresis was at 9 W constant power for 10 hours at ambient temperature. The dried gel was subjected to autoradlography for 16 hours (below). FH 15 and his mother (M) are heterozygous for the mutation in exon 5; the sequence of exon 5 in his father (F) is normal.
in these cells (Fig 3b, lane 1) . When the cells were transfected with pLDLR4, the normal human LDL receptor cDNA, immunoblotting of cell extracts revealed two major bands, one with a mobility equivalent to an apparent molecular weight of 130 kD, the same as that of the mature human receptor in cultured skin fibroblasts, and a second band with slightly faster mobility (Fig 3a,  lane 2) . The precursor protein was also visible on the immunoblot. Ligand blotting with labeled LDL showed that both high-molecular-weight bands but not the precursor protein were able to bind LDL (Fig 3b, lane 2) . In many of our previous experiments (Reference 10, and data not shown), only a single band of mature protein was visible on immunoblots of cells that expressed the normal, human LDL-receptor cDNA, and the reason for the presence of the second band was not clear. The entire DNA sequence of the plasmid was confirmed, and no mutations were found to have been introduced inadvertently. Since the level of expression was particularly high in these experiments, we concluded that the second band was either a degradation product of the mature protein or an intermediate of the precursor with incomplete modification of carbohydrate.
Mutations in the Epidermal Growth Factor (EGF)-Precursor Domain (LeusuPro, HiS Ala^Thr, and a 1-bp Deletion in Codon 651)
When the three mutant alleles that were predicted to yield single amino acid changes in the EGF-precursor domain of the protein were expressed in COS cells, in each case there was a marked effect on receptor protein synthesis or maturation. Substitution of Leus^ by Pro resulted in accumulation of a precursor protein that was not processed at all to the mature form (Fig 3a, lane 3) and did not bind LDL (Fig 3b, lane 3) . Substitution by Tyr at Hisy^ resulted in a precursor form that was processed to some extent, in that approximately equaJ amounts of mature and precursor forms were detected by immunoblotting of cell extracts (Fig 3a, lane 4) . The mature form was able to bind LDL, as shown by increased intensity of the band on the ligand blot (Fig 3b, lane 4) compared with that in extracts of mock-transfected cells (lane 1). In these two cases both the precursor and mature forms of the mutant proteins exhibited the same electrophoretic mobility as their normal counterparts. In contrast, the substitution at Ala^ by Thr resulted in the synthesis of a precursor protein with an electrophoretic mobility slightly less than normal and that was processed to some extent to a mature form with similarly reduced mobility (Fig 3a, lane 5) . Again the ligand blot showed that the mature protein retained some ability to bind LDL (Fig 3b, lane 5) . Expression of cDNA with the 1-bp deletion in exon 14, which was predicted to cause a frameshift that would introduce an additional 35 abnormal amino acids after residue 651 in repeat C of the mature protein, resulted in the accumulation of small amounts of an immunodetectable protein with a mobility equivalent to an apparent molecular weight of approximately 78 kD on the nonreduced gel (Fig 5a, lane 7) . Ligand blotting of cell extracts showed that this truncated protein retained little or no ability to bind LDL (Fig 5b, lane 7) .
Mutations in the Binding Domain (His,Ser l90 . m Pro and Cys^Tyr)
In cells that express cDNA with a single-codon deletion from repeat 5 of the binding domain (predicted to be His,9 0 ,Ser 191 to Pro), an immunodetectable precursor of normal mobility was synthesized and processed at an apparently normal rate to a mature protein with a mobility slightly faster than normal (Fig 3a, lane 6 ). This mature protein may have been less stable than normal, since the lower of the two bands of mature protein that were observed at roughly equal intensity in cells that express the normal receptor was the predominant band in these cells, which express the deletion in repeat 5. From the ligand blot it was clear that the lowermolecular-weight form of the mature protein, the major band in these cells, was unable to bind LDL (Fig 5b,  lane 6) . Although a band was present on the ligand blot at the position of the mature receptor protein, this band had an intensity equal to the band in the mock-transfected COS cells (lane 1) and was therefore derived almost entirely from the endogenous COS cell receptor.
Expression of the second mutation in the binding domain, Cysjw to Tyr, resulted in the synthesis of an immunodetectable precursor protein that accumulated to some extent and therefore probably matured slightly more slowly than normal (Fig 3a, lane 8) . The mobility of both precursor and mature forms was slightly reduced compared with that of the normal human receptor and its precursor that were expressed in COS cells (lane 2). Also visible on the immunoblot was a highmolecular-weight form of the receptor protein that may have resulted from dimerization of the receptor protein, since the mutation destroys one of a pair of Cys residues that are involved in intramolecular disulfide linkage, 3 leaving the other available to participate in increased intermolecular linkage. 27 Ligand blotting showed that the substitution abolished the ability of the receptor to bind LDL (Fig 3b, lane 8) .
Mutation in the Cytoplasmic Tail (1-bp Deletion in Codon 805)
The 1-bp deletion in exon 17 was predicted to cause a frameshift that would destroy the Asn-Pro-Val-Tyr internalization signal 28 and include an extra 104 abnormal amino acids after residue 805 in the mature protein.
When expressed in COS cells, LDL-receptor cDNA containing this mutation produced no LDL-receptor protein that could be detected either by Immunoblotting or ligand blotting of cell extracts in three separate experiments, one of which is shown in Fig 3a and 3b, lane 9, from which we concluded that this mutation would result in a null phenotype.
However, when the exon 17 mutant cDNA was expressed in CHO cells, the results were different. We have shown that the normal human LDL-receptor that is expressed in COS cells exhibits reduced degradation of labeled LDL relative to the amount bound, probably because of impaired internalization and recycling of the protein, even though the endogenous COS cell receptor apparently functions normally (B.L. Knight, PhD, et al, unpublished observations). Since we initially thought that the 1-bp deletion in exon 17 might result in an internalization-defective LDL-receptor protein, it was expressed as a stable transfectant in CHO Idl-A7 cells, which lack LDL-receptor activity. Unlike COS cells, immunoblotting of CHO cells revealed a faint band corresponding to the mature LDL receptor (Fig 3c, lane  10) ; however, ligand blotting showed that this protein was unable to bind LDL (Fig 3d, lane 10) . When cell lines that express the normal LDL-receptor cDNA were analyzed by immunoblotting, the mature receptor with a mobility slightly less than that of the endogenous protein in untransfected cells was observed (Fig 3c, lane  11) . This mature receptor protein was able to bind LDL on the ligand blot (Fig 3d, lane 11) . Stable CHO transfectants carrying the LDL-receptor cDNA with the 1-bp deletion in exon 17 expressed one major band of an immunodetectable protein with mobility equivalent to an apparent molecular weight of approximately 70 kD on nonreduced gels (Fig 3c, lane 12) and was flanked by two minor bands of similar mobility. Ligand blotting revealed that the major band retained some ability to bind LDL (Fig 3d, lane 12) , but when the metabolism of l25 I-labeled LDL by intact cells was determined, saturable binding, uptake, and degradation of LDL by cells expressing mutant cDNA were not different from those of untransfected CHO Idl-A7 cells (data not shown). Similar results were obtained with two independent lines of stably transfected cells.
Discussion
In this study, 11 mutations of the LDL-receptor gene, nine of which have not been described previously, have by guest on July 1, 2017 http://atvb.ahajournals.org/ Downloaded from been characterized in seven patients with a clinical diagnosis of homozygous FH from the Jiang-su province of China. In a recent article, Hobbs and coworkers 29 briefly describe two mutations in a compound heterozygous FH patient of Han Chinese origin; it is likely that their patient is one of those described in our study, as fibroblasts from our patient were sent to Dallas. However, although one mutant allele is identical in both studies, the other appears to differ in detail. The patient in our study was heterozygous for a deletion of a single nucleotide, thymidine in codon 651 in exon 14, whereas Hobbs et al 29 describe the mutation as a deletion of cytidine, causing a frameshift in codon 650.
In three more patients we were unable to detect any mutation in their LDL-receptor genes by Southern blotting, nucleotide sequencing, or analysis of SSCPs. We are reasonably confident that any base substitutions in the coding region or at the splice-site junctions of the gene would have been detected, and an alternative explanation is that the genetic defect does not lie in the LDL-receptor gene itself but in the gene for some other protein that is essential for normal receptor regulation or function in vivo. This could be investigated further by genetic linkage studies to identify other genes, but the Chinese families in this study are too small to be informative.
All mutations that were predicted to result in a single amino acid substitution were introduced into the LDLreceptor cDNA and expressed in COS cells; in each case the expressed protein showed some defect in structure or function that could account for defective lipoprotein metabolism in vivo, thus leading to FH. As expected, amino acid substitutions in the EGF-precursor domain affected intracellular transport of the protein, whereas those in the disulfide-rich repeats in the binding domain abolished the ability of the mutant protein to bind LDL. Of particular interest was the mutant protein derived from the allele with 1 bp deleted from codon 805 in exon 17, since the frameshift resulting from this was predicted to destroy the internalization signal. 28 No mutant protein could be detected in COS cells that transiently express mutant cDNA, but surprisingly considerable amounts of receptor protein were found in extracts of stable transfectants of CHO cells. The apparent molecular weight of approximately 70 kD for the expressed protein was less than that predicted, but occasionally trace amounts of a much larger protein could be seen (data not shown), suggesting that the 70-kD protein might be a degradation product of an unstable, full-length product. It is difficult to predict whether cells in vivo would express the mutant protein, but there is no doubt that the mutation would result in defective lipoprotein metabolism.
Despite the relative isolation of the Chinese population over many generations, we found no evidence for a founder gene effect in these FH patients from Jiang-su province. No mutation was found in more than one unrelated individual, even though each mutant allele was shown to have been inherited from a parent and was not the result of de novo mutation in that generation. Thus, the absence of clinical signs and symptoms in the obligate and identified heterozygous FH family members is not due to inheritance of one or more mutations that have a particularly mild effect on receptor function, resulting in a defect that is essentially recessive. Indeed, most of the mutations have been shown to result in a protein with little or no residual LDL-receptor activity. For example, the mother of homozygote FH4, who is heterozygous for the Leu 534 Pro mutation that results in accumulation of a precursor receptor that is unlikely to reach the cell surface, has a total plasma cholesterol level of only 4.7 mmol/L. This is barely higher than the reported mean value for total plasma cholesterol in China of 4.5 mmol/L 7 -8 and well within the normal range for Western societies. 30 Indeed, few of the heterozygous FH parents with defined mutations have a total plasma cholesterol level of twice the normal mean, as is usually found with FH heterozygotes in the West. 1 It is interesting to speculate whether genetic influences, such as the "cholesterol-lowering" gene observed by Hobbs et al 31 in a Puerto Rican family, are relatively common in this Chinese population or whether dietary and other environmental factors are responsible for the low plasma cholesterol values.
Although it is impossible to accurately determine the frequency of FH in this population, the number of FH homozygotes suggests that it is likely to be similar to that in other populations in which there is no founder effect. The Han Chinese are believed to have originated in two main areas, the Yangtze valley and the Hwang Ho valley. The majority in Jiang-su province are from the Yangtze valley group, and migration to Taiwan, Hong Kong, and the West has occurred from this same group. Thus, it is likely that the mutant LDL-receptor genes described in this study will also be found in individuals of Chinese origin now living in Europe and the United States, and it will be interesting to determine whether such FH heterozygotes are as well protected against the development of premature CHD as their counterparts in China. Comparison of individuals with the same mutation in the LDL-receptor gene who live in the two locations may provide important clues about the cause of the phenotypic variation between FH heterozygotes in other populations.
